Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
Department of Hematology, Zhongshan People's Hospital, Zhongshan 528400, China.
Immunotherapy. 2021 Jul;13(10):863-877. doi: 10.2217/imt-2020-0277. Epub 2021 May 6.
Antitumor function of the immune system has been harnessed to eradicate tumor cells as cancer therapy. Therapeutic cancer vaccines aim to help immune cells recognize tumor cells, which are difficult to target owing to immune escape. Many attempts at vaccine designs have been conducted throughout the last decades. In addition, as the advanced understanding of immunosuppressive mechanisms mediated by tumor cells, combining cancer vaccines with other immune therapies seems to be more efficient for cancer treatment. Acute myeloid leukemia (AML) is the most common acute leukemia in adults with poor prognosis. Evidence has shown T-cell-mediated immune responses in AML, which encourages the utility of immune therapies in AML. This review discusses cancer vaccines in AML from vaccine design as well as recent progress in vaccination combination with other immune therapies.
免疫系统的抗肿瘤功能已被用于消除肿瘤细胞作为癌症治疗方法。治疗性癌症疫苗旨在帮助免疫细胞识别肿瘤细胞，由于免疫逃逸，这些肿瘤细胞难以成为靶向目标。在过去的几十年中，已经进行了许多疫苗设计的尝试。此外，随着对肿瘤细胞介导的免疫抑制机制的深入了解，将癌症疫苗与其他免疫疗法相结合似乎对癌症治疗更有效。急性髓系白血病（AML）是成人中最常见的急性白血病，预后不良。有证据表明 AML 中存在 T 细胞介导的免疫反应，这鼓励了免疫疗法在 AML 中的应用。本综述讨论了 AML 中的癌症疫苗，包括疫苗设计以及与其他免疫疗法联合接种的最新进展。
